Aptus Clinical signs consulting contract with ValiRx plc

ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company’s clinical team has signed an agreement to work with Aptus Clinical Ltd (“Aptus”), the UK based, clinical Contract Research Organisation (“CRO”), to effectuate a…

NHS patients to get faster access to pioneering treatments

New improvements to the Accelerated Access Collaborative (AAC) will put the most promising medicines, diagnostic tools and digital services through the clinical development and regulatory approval process faster. The AAC was set up in 2018 to speed up the time it takes for…

How Viedoc helps us optimise data capture and reduce our study lead times

Paul Blaney, Digital Health Lead at Aptus Clinical, explains why, having evaluated six EDC systems, they opted for Viedoc. https://www.viedoc.com/blog/functionality-and-usability-reduce-lead-times-the-reason-cro-aptus-clinical-chose-viedoc/

Our growth story

Since its inception in 2014, specialist clinical Contract Research Organisation, Aptus Clinical has grown from strength to strength. Having won BioNow’s Start-up of the year in 2016 and been a shortlisted finalist for OBN’s Specialist CRO of the Year in…

Why are we based at Alderley Park?

Alderley Park has been the home of scientific innovation for decades, particularly for oncology research. Here a number of contributors, including our CEO Steve McConchie, explain the advantages of building a business here.

After the ‘Meaningful Vote’, MHRA guidance in event of a no-deal Brexit scenario

Following the ‘Meaningful Vote’ on the 15th of January, in which MPs voted down the Prime Minister Theresa May’s Brexit Deal, Aptus Clinical would like to reiterate the updated guidance from the MHRA in the event of a no deal…

Aptus Clinical receive £150k from NPIF-FW Capital Debt Finance

Aptus Clinical, a specialist clinical contract research organisation based at Alderley Park, has received a £150k loan from the Northern Powerhouse Investment Fund (NPIF) – FW Capital Debt Finance, managed by FW Capital and part of the NPIF. The growth…

Cell & Gene Therapy Catapult Partnership

APTUS CLINICAL AND THE CELL AND GENE THERAPY CATAPULT ANNOUNCE THEIR CLINICAL SERVICE PARTNERSHIP TO SUPPORT ADVANCED THERAPY DEVELOPMENT IN THE UK Following a rigorous selection process Aptus Clinical have been appointed as a supplier for Clinical Services by the…

Do you know our Values?

Great to see our friends at Blueberry Therapeutics achieve this

http://www.blueberrytherapeutics.com/blueberry-therapeutics-limited-closes-10m-funding-to-support-development-of-nanomedicines-portfolio/